Browse ARPP21

Summary
SymbolARPP21
NamecAMP-regulated phosphoprotein, 21kDa
Aliases ARPP-21; TARPP; R3HDM3; R3H domain containing 3; RCS; cyclic AMP-regulated phosphoprotein, 21 kD; thymocyte ......
Chromosomal Location3p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm
Domain PF01424 R3H domain
PF12752 SUZ domain
Function

Isoform 2 may act as a competitive inhibitor of calmodulin-dependent enzymes such as calcineurin in neurons.

> Gene Ontology
 
Biological Process GO:0009266 response to temperature stimulus
GO:0009408 response to heat
GO:0034605 cellular response to heat
Molecular Function GO:0005516 calmodulin binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolARPP21
NamecAMP-regulated phosphoprotein, 21kDa
Aliases ARPP-21; TARPP; R3HDM3; R3H domain containing 3; RCS; cyclic AMP-regulated phosphoprotein, 21 kD; thymocyte ......
Chromosomal Location3p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ARPP21 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolARPP21
NamecAMP-regulated phosphoprotein, 21kDa
Aliases ARPP-21; TARPP; R3HDM3; R3H domain containing 3; RCS; cyclic AMP-regulated phosphoprotein, 21 kD; thymocyte ......
Chromosomal Location3p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ARPP21 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolARPP21
NamecAMP-regulated phosphoprotein, 21kDa
Aliases ARPP-21; TARPP; R3HDM3; R3H domain containing 3; RCS; cyclic AMP-regulated phosphoprotein, 21 kD; thymocyte ......
Chromosomal Location3p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ARPP21 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1880.656
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.20.776
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1830.761
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1040.907
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1820.908
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.4770.777
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0750.938
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0490.975
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0420.981
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-1.2030.127
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-1.2030.254
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0550.846
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ARPP21 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.79.6-5.90.679
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.710.2-6.50.425
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.317.6-3.31
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.516.7-4.21
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.418.2-2.81
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916012.5-12.50.52
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59022.2-22.20.505
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382715.8015.80.037
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221318.2018.20.274
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.5012.50.485
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolARPP21
NamecAMP-regulated phosphoprotein, 21kDa
Aliases ARPP-21; TARPP; R3HDM3; R3H domain containing 3; RCS; cyclic AMP-regulated phosphoprotein, 21 kD; thymocyte ......
Chromosomal Location3p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ARPP21. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolARPP21
NamecAMP-regulated phosphoprotein, 21kDa
Aliases ARPP-21; TARPP; R3HDM3; R3H domain containing 3; RCS; cyclic AMP-regulated phosphoprotein, 21 kD; thymocyte ......
Chromosomal Location3p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ARPP21. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ARPP21.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolARPP21
NamecAMP-regulated phosphoprotein, 21kDa
Aliases ARPP-21; TARPP; R3HDM3; R3H domain containing 3; RCS; cyclic AMP-regulated phosphoprotein, 21 kD; thymocyte ......
Chromosomal Location3p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ARPP21. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolARPP21
NamecAMP-regulated phosphoprotein, 21kDa
Aliases ARPP-21; TARPP; R3HDM3; R3H domain containing 3; RCS; cyclic AMP-regulated phosphoprotein, 21 kD; thymocyte ......
Chromosomal Location3p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ARPP21 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolARPP21
NamecAMP-regulated phosphoprotein, 21kDa
Aliases ARPP-21; TARPP; R3HDM3; R3H domain containing 3; RCS; cyclic AMP-regulated phosphoprotein, 21 kD; thymocyte ......
Chromosomal Location3p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ARPP21 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolARPP21
NamecAMP-regulated phosphoprotein, 21kDa
Aliases ARPP-21; TARPP; R3HDM3; R3H domain containing 3; RCS; cyclic AMP-regulated phosphoprotein, 21 kD; thymocyte ......
Chromosomal Location3p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ARPP21 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.